New Lease Of Life For Merck Serono Reject Cilengitide
Basing a company around a high-profile failed drug candidate is not for the faint hearted, but that's exactly what Dr. John March is doing with Merck Serono reject cilengitide. Scrip asked him what it will take to turn the cilengitide story around.
You may also be interested in...
Merck KGaA's investigational drug for glioblastoma, the first-in-class integrin inhibitor cilengitide, has failed to meet its primary endpoint in a 500-patient Phase III trial. Flagged by Datamonitor last year as a key hope for the German firm's future revenue growth, cilengitide has not been officially discontinued - a Phase II trial in a subset of patients is continuing with data expected this year - but the drug's prospects look dim.
The UK's main reimbursement bodies made a series of decisions this week that were broadly favorable and largely focused on oncology medicines.
While troubled Valeant was divesting iNova to private equity investors, Novartis announced a pair of oncology-focused deals, out-licensing a brain cancer drug to Midatech and partnering with IBM Watson Health to optimize breast cancer treatment.